FDA Widens Path for Rare-Disease Treatments With New Approval – The Wall Street Journal

1. FDA Widens Path for Rare-Disease Treatments With New Approval The Wall Street Journal
2. RETA Stock Skyrockets As FDA Approves Reata Phama’s Neurological Drug | Investor’s Business Daily Investor’s Business Daily
3. Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia Business Wire
4. FDA approves Reata’s treatment for rare neurological disease STAT
5. Reata Pharmaceuticals up 192% on Friedreich’s ataxia drug omaveloxolone approval (RETA) Seeking Alpha
6. View Full Coverage on Google News

Read original article here